News Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Delayed Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
16.78 ^USD	+2.88%		+1.70%	+64.67%

Jul. 01	Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) added to Russell Small Cap Comp Growth Index	CI
Jun. 02	Transcript : Cullinan Therapeutics, Inc. - Special Call

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Transcript : Cullinan Therapeutics, Inc. - Special Call	Jun. 01
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib	Jun. 01	AQ
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib	Jun. 01	GL
Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib	Jun. 01	CI
Cullinan Therapeutics : Full Pipeline Overview	May. 31	PU
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit	May. 24	GL
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024	May. 23	GL
Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	May. 15	GL
Cullinan Therapeutics, Inc. Announces Board Changes	May. 15	CI
Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing	May. 09	MT
Cullinan Therapeutics, Inc. announced that it has received $280.000024 million in funding from a group of investors	Apr. 29	CI
Cullinan Therapeutics Appoints Mary Kay Fenton as CFO	Apr. 29	MT
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer	Apr. 29	GL
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer	Apr. 29	AQ
Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer	Apr. 29	CI
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024	Apr. 24	GL
Cullinan Oncology : Therapeutics Corporate Update	Apr. 16	PU
Transcript : Cullinan Oncology, Inc. - Special Call	Apr. 16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Summary

Filters